Minireviews
Copyright ©The Author(s) 2021.
World J Gastroenterol. May 21, 2021; 27(19): 2312-2324
Published online May 21, 2021. doi: 10.3748/wjg.v27.i19.2312
Table 1 The risk of hepatitis B virus reactivation in patients treated with interleukin-12/23 or interleukin-23 inhibitors
Ref.
Number of HBV patients
HBV status
Disease
Drugs
Prophylaxis
Follow-up
HBV reactivation
Ting et al[27], 201854(1) 10 CHB; and (2) 44 resolved HBV. HBV-DNA at baseline (-)PsoriasisUstekinumabYes: 2 patients with CHB24 mo(1) 2 patients with CHB without prophylaxis. (no hepatitis); and (2) 1 patient with resolved HBV (mild hepatitis)
Solay et al[5], 20182929 resolved HBV. HBV-DNA at baseline (-)Psoriasis/HS/AS/RA/CDUstekinumab (n = 7)NA 22 wk1 patient with psoriasis without prophylaxis (no data regarding hepatitis)
Sanz-Bueno et al[68], 20152020 resolved HBV. HBV-DNA at baseline (-) but viral load was assessed in 7 of 20 patientsPsoriasisUstekinumab (n = 6)No40 mo0
Chiu et al[28], 201314(1) 11 CHB; and (2) 3 resolved HBV. HBV-DNA at baseline was not availablePsoriasisUstekinumabYes: 4 patients with CHB10 mo(1) 2 patients with CHB without prophylaxis (No hepatitis); and (2) 0
Navarro et al[69], 201355 CHBPsoriasisUstekinumab (n = 1)Yes25 mo0
Hayashi et al[70], 201455 resolved HBV. HBV-DNA at baseline was not availablePsoriasisUstekinumabNo52 wk0
Koskinas et al[41], 20131Resolved HBV. HBV-DNA at baseline was not availablePsoriasisUstekinumabNo16 mo1 with hepatitis (ALT 65 IU/mL)
Steglich et al[71], 20141Resolved HBV. HBV-DNA at baseline (-)PsoriasisUstekinumabYes36 mo0
Duncan et al[43], 20191Resolved HBV. HBV-DNA at baseline was not availablePalmoplantar PsoriasisGuselkumabNo12 mo0